Molbio Diagnostics Ltd 07 Nov 2026 12:00 AM
Molbio Diagnostics Ltd consolidated sales down 36.57% on year in Q2FY2027, net profit tanked by 85.40%,
Molbio Diagnostics Ltd share price slipped 4.50% to Rs 1340.9 after the company`s net profit plunged by 85.40% to Rs 7.7 crore, while revenue from operations nosedived 36.57% to Rs 259.02 crore in Q2FY27 over Q2FY26. The market capitalization of Medical Equipment & Supplies industry group stocks on BSE stood at Rs 24472.48 crore, slipping 0.98%. It has improved by 8.31% over last one week and surged by 79.12% in last one month while the market capitalization of Molbio Diagnostics Ltd has remained flat Profit before tax (PBT) of Molbio Diagnostics Ltd stood at Rs 17.51 crore in Q2 FY27, plunging by 155.98% year-on-year, and crashing by 76.93% quarter-on-quarter. EBITDA came in at Rs 38 crore, tanking 338.33% YoY and tumbling by 60.84% sequentially. Total expenses slumped by 26.61% to Rs 238.43 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 113.0 crore, contracting by 14.05% YoY, while employee benefits expense was at Rs 37.8 crore, tanking by 17.68% YoY. For FY26, revenue from operations witnessed a strong growth of 41.68% to Rs 1445.69 crore, while net profit expanded by 18.44% to Rs 164.14 crore, compared to previous FY. EBITDA surged by 27279% to Rs 311.96 crore, and PBT rose 18.88% to Rs 231.14 crore compared to previous FY. The company`s consolidated net cash flow from operating activities stood at Rs 50.39 crore in FY26, as against Rs 287.1 crore in FY25.
Molbio Diagnostics Ltd 02 Nov 2026 12:00 AM
Molbio Diagnostics schedules a board meeting November 5 to review financial results,
Molbio Diagnostics Limited will hold a board meeting on November 5, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2026, and the trading window for the company`s shares remains closed from October 1, 2026, until 48 hours after the results are declared.
Molbio Diagnostics Ltd 08 Oct 2026 12:00 AM
Molbio Diagnostics confirms electronic shareholding via KFin Technologies for September quarter,
Molbio Diagnostics Limited informed the BSE Limited and National Stock Exchange of India Ltd that KFin Technologies Limited, its Registrar and Share Transfer Agent, has issued a certificate for the quarter ended September 30, 2026, as per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming that the entire holding of the company was in electronic mode and no rematerialisation requests were received during the period.
Molbio Diagnostics Ltd 28 Sep 2026 12:00 AM
Molbio Diagnostics closes trading window for insiders ahead of quarterly results,
Molbio Diagnostics Limited informed the BSE Limited and National Stock Exchange of India Ltd that the trading window for dealing in the company`s securities will be closed for all insiders and designated persons and their immediate relatives from October 01, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ended September 30, 2026.
Molbio Diagnostics Ltd 25 Sep 2026 12:00 AM
Molbio Diagnostics` board re-appointed K. S. Kamalakara & Co as Cost Auditors,
Molbio Diagnostics Limited informed the Bombay Stock Exchange and National Stock Exchange of India that its board of directors approved the re-appointment of M/s K. S. Kamalakara & Co, a Peer-reviewed firm with Firm Reg. No: 000296, as the Cost Auditors of the company for the financial year 2026-27.
Subscribe for our
newsletter
Open Account Now